Financial results for the first half of 2006
New TLR assets from Schering-Plough Corporation and advanced R&D collaboration with IGR
Strategic partnership with Novo Nordisk to research and develop drugs targeting NK
Number of shares and voting rights, as of December 31, 2007
Refocus of partnership with Novo Nordisk A/S
Operating revenue of 14.2 million euros in 2007
Financial results for 2007
Recruitment of CBO and start of operations in the USA
Turnover of 1.5 million euros for the first quarter of 2008
IPH 2301 enters into regulatory pre-clinical development
